Oragenics, Inc. (OGEN)
| Market Cap | 4.64M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.57M |
| Shares Out | 21.48M |
| EPS (ttm) | -1.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 274,237 |
| Open | 0.2250 |
| Previous Close | 0.2300 |
| Day's Range | 0.2116 - 0.2298 |
| 52-Week Range | 0.2116 - 3.4300 |
| Beta | 0.85 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 14, 2025 |
About OGEN
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibioti... [Read more]
Financial Performance
Financial StatementsNews
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry Momentum ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundatio...
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
SARASOTA, Fla., March 18, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, to...
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
SARASOTA, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, to...
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment
SARASOTA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, tod...
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
Collaboration Aims to Develop First Intranasal Therapy for Mild Traumatic Brain Injury Aka Concussion, Establishing a Comprehensive Test-to-Treat Platform Collaboration Aims to Develop First Intranasa...
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
SARASOTA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, tod...
Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO
SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an ...
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference
SARASOTA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today announced the convers...
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be present...
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided ...
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
SARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, has completed a key study fo...
Oragenics, Inc. Announces Closing of Public Offering
SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders...
Oragenics, Inc. Announces Pricing of Public Offering
SARASOTA, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders...
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients • No pharmaceutical treatment is available for conc...
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurolo...
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
• ONP-002 stability eliminates need for cumbersome cold storage • No FDA-approved pharmaceutical treatment available for concussion
Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study
– ONP-002 showed no cancer-causing DNA damage – Phase II clinical trial being planned SARASOTA, Fla., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on deve...
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globally The potential addressable market opportunity for ONP-002 includes an estimated 69 million...
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders,...
Oragenics, Inc. Announces Proposed Public Offering
SARASOTA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of n...
Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer
Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emergency Department Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emerg...
Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today anno...
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...
Oragenics, Inc. Files 10K and Provides Company Update
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (the “Company”) (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, ...
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...